{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:34:47Z","timestamp":1776868487907,"version":"3.51.2"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Anaplastic thyroid carcinoma (ATC) is among the most lethal thyroid malignancies, with poor clinical outcomes and limited treatment strategies. To gain insights into the molecular mechanisms involved in its progression, we performed an integrative bioinformatic analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We analyzed five microarray datasets from the GEO database to compare gene expression profiles between ATC samples and normal thyroid tissues. Differentially expressed genes (DEGs) were identified using GEO2R, and overlapping genes across datasets were detected through Venn diagram analysis. Functional enrichment was performed using DAVID and Metascape. A protein\u2013protein interaction (PPI) network was constructed with STRING, and significant gene modules were identified using the MCODE plugin in Cytoscape. Co-expression analysis was further explored with GeneMANIA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We identified 7532 DEGs, of which 3509 were upregulated and 4023 were downregulated. Upregulated genes were mainly involved in cell division and mitotic control, while downregulated genes were related to thyroid hormone production and gland development. Six hub genes stood out for their centrality in the network: TPX2, MAD2L1, CDC20, CDKN3, CENPF, and NEK2.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our findings shed light on key genes and pathways that may contribute to ATC pathogenesis. These results provide a foundation for identifying potential diagnostic biomarkers and therapeutic targets for this aggressive cancer.\n<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s43046-025-00282-2","type":"journal-article","created":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T23:01:52Z","timestamp":1747004512000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Integrative bioinformatic analysis identifies differentially expressed gene targets as potential biomarkers for anaplastic thyroid cancer"],"prefix":"10.1186","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6366-307X","authenticated-orcid":false,"given":"Angel Sebastian","family":"Trevi\u00f1o-Juarez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Gerardo","family":"Gonzalez-Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rene","family":"Rodriguez-Gutierrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Sanchez-Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilo Daniel","family":"Gonzalez-Velazquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"issue":"4","key":"282_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22041950","volume":"22","author":"J Hu","year":"2021","unstructured":"Hu J, Yuan IJ, Mirshahidi S, et al. Thyroid carcinoma: phenotypic features, underlying biology and potential relevance for targeting therapy. Int J Mol Sci. 2021;22(4): 1950. https:\/\/doi.org\/10.3390\/ijms22041950.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"282_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin"},{"issue":"9356","key":"282_CR3","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/s0140-6736(03)12488-9","volume":"361","author":"SI Sherman","year":"2003","unstructured":"Sherman SI. Thyroid carcinoma. Lancet Lond Engl. 2003;361(9356):501\u201311. https:\/\/doi.org\/10.1016\/s0140-6736(03)12488-9.","journal-title":"Lancet Lond Engl"},{"issue":"9","key":"282_CR4","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1002\/ijc.29251","volume":"136","author":"C La Vecchia","year":"2015","unstructured":"La Vecchia C, Malvezzi M, Bosetti C, et al. Thyroid cancer mortality and incidence: a global overview. Int J Cancer. 2015;136(9):2187\u201395. https:\/\/doi.org\/10.1002\/ijc.29251.","journal-title":"Int J Cancer"},{"issue":"1","key":"282_CR5","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12943-018-0903-0","volume":"17","author":"S Saini","year":"2018","unstructured":"Saini S, Tulla K, Maker AV, et al. Therapeutic advances in anaplastic thyroid cancer: a current perspective. Mol Cancer. 2018;17(1):154. https:\/\/doi.org\/10.1186\/s12943-018-0903-0.","journal-title":"Mol Cancer"},{"key":"282_CR6","doi-asserted-by":"publisher","DOI":"10.1177\/20420188211054692","volume":"12","author":"SS Agosto","year":"2021","unstructured":"Agosto SS. Evolution of anaplastic thyroid cancer management: perspectives in the era of precision oncology. Ther Adv Endocrinol Metab. 2021;12: 20420188211054692. https:\/\/doi.org\/10.1177\/20420188211054692.","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"1","key":"282_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-15-293","volume":"15","author":"P Bardou","year":"2014","unstructured":"Bardou P, Mariette J, Escudi\u00e9 F, et al. jvenn: an interactive Venn diagram viewer. BMC Bioinformatics. 2014;15(1): 293. https:\/\/doi.org\/10.1186\/1471-2105-15-293.","journal-title":"BMC Bioinformatics"},{"issue":"1","key":"282_CR8","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523. https:\/\/doi.org\/10.1038\/s41467-019-09234-6.","journal-title":"Nat Commun"},{"issue":"W1","key":"282_CR9","doi-asserted-by":"publisher","first-page":"W216","DOI":"10.1093\/nar\/gkac194","volume":"50","author":"BT Sherman","year":"2022","unstructured":"Sherman BT, Hao M, Qiu J, et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022;50(W1):W216-221. https:\/\/doi.org\/10.1093\/nar\/gkac194.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"282_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"DW Huang","year":"2009","unstructured":"Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44\u201357. https:\/\/doi.org\/10.1038\/nprot.2008.211.","journal-title":"Nat Protoc"},{"issue":"2","key":"282_CR11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.cell.2015.06.014","volume":"162","author":"J-H Wei","year":"2015","unstructured":"Wei J-H, Zhang ZC, Wynn RM, et al. GM130 regulates golgi-derived spindle assembly by activating TPX2 and capturing microtubules. Cell. 2015;162(2):287\u201399. https:\/\/doi.org\/10.1016\/j.cell.2015.06.014.","journal-title":"Cell"},{"issue":"1","key":"282_CR12","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41467-019-14087-0","volume":"11","author":"MR King","year":"2020","unstructured":"King MR, Petry S. Phase separation of TPX2 enhances and spatially coordinates microtubule nucleation. Nat Commun. 2020;11(1):270. https:\/\/doi.org\/10.1038\/s41467-019-14087-0.","journal-title":"Nat Commun"},{"issue":"21","key":"282_CR13","doi-asserted-by":"publisher","first-page":"6519","DOI":"10.1158\/1078-0432.CCR-09-0077","volume":"15","author":"SL Warner","year":"2009","unstructured":"Warner SL, Stephens BJ, Nwokenkwo S, et al. Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15(21):6519\u201328. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0077.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"9","key":"282_CR14","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1158\/1078-0432.CCR-09-2214","volume":"16","author":"R Satow","year":"2010","unstructured":"Satow R, Shitashige M, Kanai Y, et al. Combined functional genome survey of therapeutic targets for hepatocellular carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2010;16(9):2518\u201328. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-2214.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"1","key":"282_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12957-016-1095-y","volume":"15","author":"C Tomii","year":"2017","unstructured":"Tomii C, Inokuchi M, Takagi Y, et al. TPX2 expression is associated with poor survival in gastric cancer. World J Surg Oncol. 2017;15(1):14. https:\/\/doi.org\/10.1186\/s12957-016-1095-y.","journal-title":"World J Surg Oncol"},{"issue":"1\u20134","key":"282_CR16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.bbrc.2018.10.164","volume":"507","author":"M Chen","year":"2018","unstructured":"Chen M, Zhang H, Zhang G, et al. Targeting TPX2 suppresses proliferation and promotes apoptosis via repression of the PI3k\/AKT\/P21 signaling pathway and activation of p53 pathway in breast cancer. Biochem Biophys Res Commun. 2018;507(1\u20134):74\u201382. https:\/\/doi.org\/10.1016\/j.bbrc.2018.10.164.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"282_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-313","volume":"11","author":"P Wei","year":"2013","unstructured":"Wei P, Zhang N, Xu Y, et al. TPX2 is a novel prognostic marker for the growth and metastasis of colon cancer. J Transl Med. 2013;11(1): 313. https:\/\/doi.org\/10.1186\/1479-5876-11-313.","journal-title":"J Transl Med"},{"issue":"10","key":"282_CR18","doi-asserted-by":"publisher","first-page":"18148","DOI":"10.3390\/ijms151018148","volume":"15","author":"Y Huang","year":"2014","unstructured":"Huang Y, Guo W, Kan H. TPX2 is a prognostic marker and contributes to growth and metastasis of human hepatocellular carcinoma. Int J Mol Sci. 2014;15(10):18148\u201361. https:\/\/doi.org\/10.3390\/ijms151018148.","journal-title":"Int J Mol Sci"},{"key":"282_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbrc.2021.01.106","volume":"546","author":"B Zhang","year":"2021","unstructured":"Zhang B, Zhang M, Li Q, et al. TPX2 mediates prostate cancer epithelial-mesenchymal transition through CDK1 regulated phosphorylation of ERK\/GSK3\u03b2\/SNAIL pathway. Biochem Biophys Res Commun. 2021;546:1\u20136. https:\/\/doi.org\/10.1016\/j.bbrc.2021.01.106.","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"282_CR20","doi-asserted-by":"publisher","first-page":"e0136246","DOI":"10.1371\/journal.pone.0136246","volume":"10","author":"Z Wang","year":"2015","unstructured":"Wang Z, Katsaros D, Shen Y, et al. Biological and clinical significance of MAD2L1 and BUB1, genes frequently appearing in expression signatures for breast cancer prognosis. Coleman WB. ed. PLOS ONE. 2015;10(8):e0136246. https:\/\/doi.org\/10.1371\/journal.pone.0136246.","journal-title":"PLOS ONE"},{"issue":"9","key":"282_CR21","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1136\/jmg.2009.074252","volume":"47","author":"Y Guo","year":"2010","unstructured":"Guo Y, Zhang X, Yang M, et al. Functional evaluation of missense variations in the human MAD1L1 and MAD2L1 genes and their impact on susceptibility to lung cancer. J Med Genet. 2010;47(9):616\u201322. https:\/\/doi.org\/10.1136\/jmg.2009.074252.","journal-title":"J Med Genet"},{"issue":"4","key":"282_CR22","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/1098-2264(2000)9999:9999<::AID-GCC1044>3.0.CO;2-N","volume":"29","author":"MJ Percy","year":"2000","unstructured":"Percy MJ, Myrie KA, Neeley CK, et al. Expression and mutational analyses of the humanMAD2L1 gene in breast cancer cells. Genes Chromosomes Cancer. 2000;29(4):356\u201362. https:\/\/doi.org\/10.1002\/1098-2264(2000)9999:9999%3c::AID-GCC1044%3e3.0.CO;2-N.","journal-title":"Genes Chromosomes Cancer"},{"key":"282_CR23","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.pharmthera.2015.04.002","volume":"151","author":"L Wang","year":"2015","unstructured":"Wang L, Zhang J, Wan L, et al. Targeting Cdc20 as a novel cancer therapeutic strategy. Pharmacol Ther. 2015;151:141\u201351. https:\/\/doi.org\/10.1016\/j.pharmthera.2015.04.002.","journal-title":"Pharmacol Ther"},{"key":"282_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1017864","volume":"12","author":"F Xian","year":"2022","unstructured":"Xian F, Yang X, Xu G. Prognostic significance of CDC20 expression in malignancy patients: a meta-analysis. Front Oncol. 2022;12: 1017864. https:\/\/doi.org\/10.3389\/fonc.2022.1017864.","journal-title":"Front Oncol"},{"key":"282_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/1533033820962135","volume":"19","author":"L Li","year":"2020","unstructured":"Li L, Zhu M, Huang H, et al. Identification of hub genes in anaplastic thyroid carcinoma: evidence from bioinformatics analysis. Technol Cancer Res Treat. 2020;19: 1533033820962135. https:\/\/doi.org\/10.1177\/1533033820962135.","journal-title":"Technol Cancer Res Treat"},{"issue":"3","key":"282_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjoto.2020.102434","volume":"41","author":"Y-G Ding","year":"2020","unstructured":"Ding Y-G, Ren Y-L, Xu Y-S, et al. Identification of key candidate genes and pathways in anaplastic thyroid cancer by bioinformatics analysis. Am J Otolaryngol. 2020;41(3): 102434. https:\/\/doi.org\/10.1016\/j.amjoto.2020.102434.","journal-title":"Am J Otolaryngol"},{"key":"282_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.mgene.2020.100690","volume":"24","author":"LD Naorem","year":"2020","unstructured":"Naorem LD, Pathak E, Muthaiyan M, et al. Network-based meta-analysis for the identification of potential target for human anaplastic thyroid carcinoma. Meta Gene. 2020;24: 100690. https:\/\/doi.org\/10.1016\/j.mgene.2020.100690.","journal-title":"Meta Gene"},{"key":"282_CR28","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.2147\/CMAR.S193793","volume":"11","author":"J Wang","year":"2019","unstructured":"Wang J, Che W, Wang W, et al. CDKN3 promotes tumor progression and confers cisplatin resistance via RAD51 in esophageal cancer. Cancer Manag Res. 2019;11:3253\u201364. https:\/\/doi.org\/10.2147\/CMAR.S193793.","journal-title":"Cancer Manag Res"},{"issue":"3","key":"282_CR29","doi-asserted-by":"publisher","first-page":"E497","DOI":"10.1210\/jc.2013-1512","volume":"99","author":"JM Pita","year":"2014","unstructured":"Pita JM, Figueiredo IF, Moura MM, et al. Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas. J Clin Endocrinol Metab. 2014;99(3):E497\u2013507. https:\/\/doi.org\/10.1210\/jc.2013-1512.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"282_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111611","volume":"9","author":"Q Chen","year":"2014","unstructured":"Chen Q, Chen K, Guo G, et al. A critical role of CDKN3 in Bcr-Abl-mediated tumorigenesis. PLoS ONE. 2014;9(10): e111611. https:\/\/doi.org\/10.1371\/journal.pone.0111611.","journal-title":"PLoS ONE"},{"key":"282_CR31","doi-asserted-by":"publisher","first-page":"9787","DOI":"10.2147\/CMAR.S250792","volume":"12","author":"S Wang","year":"2020","unstructured":"Wang S, Wu J, Guo C, et al. Identification and validation of novel genes in anaplastic thyroid carcinoma via bioinformatics analysis. Cancer Manag Res. 2020;12:9787\u201399. https:\/\/doi.org\/10.2147\/CMAR.S250792.","journal-title":"Cancer Manag Res"},{"issue":"6","key":"282_CR32","first-page":"2690","volume":"25","author":"J Zhou","year":"2020","unstructured":"Zhou J, Dong S, Shi C. Identification of key pathways and biomarkers in anaplastic thyroid cancer using an integrated analysis. J BUON Off J Balk Union Oncol. 2020;25(6):2690\u20139.","journal-title":"J BUON Off J Balk Union Oncol"},{"issue":"4","key":"282_CR33","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3892\/etm.2021.9832","volume":"21","author":"Y Han","year":"2021","unstructured":"Han Y, Xu S, Cheng K, et al. CENPF promotes papillary thyroid cancer progression by mediating cell proliferation and apoptosis. Exp Ther Med. 2021;21(4):401. https:\/\/doi.org\/10.3892\/etm.2021.9832.","journal-title":"Exp Ther Med"},{"issue":"40","key":"282_CR34","doi-asserted-by":"publisher","first-page":"6184","DOI":"10.1038\/sj.onc.1205711","volume":"21","author":"AM Fry","year":"2002","unstructured":"Fry AM. The Nek2 protein kinase: a novel regulator of centrosome structure. Oncogene. 2002;21(40):6184\u201394. https:\/\/doi.org\/10.1038\/sj.onc.1205711.","journal-title":"Oncogene"},{"issue":"7","key":"282_CR35","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1080\/15384101.2016.1152430","volume":"15","author":"Y Fang","year":"2016","unstructured":"Fang Y, Zhang X. Targeting NEK2 as a promising therapeutic approach for cancer treatment. Cell Cycle. 2016;15(7):895\u2013907. https:\/\/doi.org\/10.1080\/15384101.2016.1152430.","journal-title":"Cell Cycle"},{"issue":"1","key":"282_CR36","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ccr.2012.12.001","volume":"23","author":"W Zhou","year":"2013","unstructured":"Zhou W, Yang Y, Xia J, et al. NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell. 2013;23(1):48\u201362. https:\/\/doi.org\/10.1016\/j.ccr.2012.12.001.","journal-title":"Cancer Cell"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-025-00282-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-025-00282-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-025-00282-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T23:01:52Z","timestamp":1747004512000},"score":1,"resource":{"primary":{"URL":"https:\/\/jenci.springeropen.com\/articles\/10.1186\/s43046-025-00282-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["282"],"URL":"https:\/\/doi.org\/10.1186\/s43046-025-00282-2","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"assertion":[{"value":"23 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}